At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 769 enrolled
Drug / intervention
Rocatinlimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD)
In Brief
A Phase 3 clinical trial evaluating Rocatinlimab and Placebo for Atopic Dermatitis. Completed, enrolled 769 participants across 202 sites in 21 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesArgentina, Brazil, Canada, China, Croatia, Czechia, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartMay 2022
First PostedJun 2022
Primary CompletionNov 2024
Study CompletionJan 2025
TodayJul 2026
First PostedJun 1, 2022
Enrollment StartMay 31, 2022
Primary CompletionNov 28, 2024
Study CompletionJan 13, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.1 years ago
Interventions
Rocatinlimabdrug
Participants will receive Rocatinlimab subcutaneously.
Placebodrug
Participants will receive a placebo subcutaneously.